Title: CDH1 genetic variants and its aberrant expression are the risk factors for colorectal cancer
metastasis
Version: 3 Date: 09 Dec 2024
Reviewer:  Ehsan Nazemalhosseini-Mojarad
Reviewer's report:
Dear Authors,
Thank you for sharing your manuscript, "CDH1 genetic variants and its aberrant expression are
the risk factors for colorectal cancer metastasis." I thoroughly enjoyed reading it and would like
to commend you on the depth of your research and the clarity of your writing. The study provides
valuable insights into the role of CDH1 polymorphisms in colorectal cancer, and I found the
methodology and discussion well-articulated.
That said, I have a concern regarding the genotyping study. In my view, a sample size of
99 patients may limit the accuracy and generalizability of the findings. Genotyping studies,
particularly those exploring associations with complex traits like cancer susceptibility, often
require larger sample sizes to achieve sufficient statistical power and account for population
variability. This is especially important to ensure the robustness of conclusions about genetic
polymorphisms and their clinical implications.
I appreciate the work you've put into this research and encourage you to consider expanding the
sample size in future studies or performing additional analyses (e.g., meta-analysis or validation
cohorts) to strengthen the impact of your findings.
Thank you for the opportunity to review your manuscript. I look forward to seeing more of your
excellent research in this field.
Best regards,
Ehsan
Title: CDH1 genetic variants and its aberrant expression are the risk factors for colorectal cancer
metastasis
Version: 3 Date: 09 Dec 2024
Reviewer:  Ehsan Nazemalhosseini-Mojarad
Reviewer's report:
Dear Authors,
Thank you for sharing your manuscript, "CDH1 genetic variants and its aberrant expression are
the risk factors for colorectal cancer metastasis." I thoroughly enjoyed reading it and would like
to commend you on the depth of your research and the clarity of your writing. The study provides
valuable insights into the role of CDH1 polymorphisms in colorectal cancer, and I found the
methodology and discussion well-articulated.
That said, I have a concern regarding the genotyping study. In my view, a sample size of
99 patients may limit the accuracy and generalizability of the findings. Genotyping studies,
particularly those exploring associations with complex traits like cancer susceptibility, often
require larger sample sizes to achieve sufficient statistical power and account for population
variability. This is especially important to ensure the robustness of conclusions about genetic
polymorphisms and their clinical implications.
I appreciate the work you've put into this research and encourage you to consider expanding the
sample size in future studies or performing additional analyses (e.g., meta-analysis or validation
cohorts) to strengthen the impact of your findings.
Thank you for the opportunity to review your manuscript. I look forward to seeing more of your
excellent research in this field.
Best regards,
Ehsan
Please review this paper.
user
Title: CDH1 genetic variants and its aberrant expression are the risk factors for colorectal cancer
metastasis
Version: 3 Date: 09 Dec 2024
Reviewer:  Ehsan Nazemalhosseini-Mojarad
Reviewer's report:
Dear Authors,
Thank you for sharing your manuscript, "CDH1 genetic variants and its aberrant expression are
the risk factors for colorectal cancer metastasis." I thoroughly enjoyed reading it and would like
to commend you on the depth of your research and the clarity of your writing. The study provides
valuable insights into the role of CDH1 polymorphisms in colorectal cancer, and I found the
methodology and discussion well-articulated.
That said, I have a concern regarding the genotyping study. In my view, a sample size of
99 patients may limit the accuracy and generalizability of the findings. Genotyping studies,
particularly those exploring associations with complex traits like cancer susceptibility, often
require larger sample sizes to achieve sufficient statistical power and account for population
variability. This is especially important to ensure the robustness of conclusions about genetic
polymorphisms and their clinical implications.
I appreciate the work you've put into this research and encourage you to consider expanding the
sample size in future studies or performing additional analyses (e.g., meta-analysis or validation
cohorts) to strengthen the impact of your findings.
Thank you for the opportunity to review your manuscript. I look forward to seeing more of your
excellent research in this field.
Best regards,
Ehsan
assistant